CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Vividion Therapeutics, Inc.
CHA University
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Seagen Inc.
Merck Sharp & Dohme LLC
Daiichi Sankyo
PMV Pharmaceuticals, Inc
Mayo Clinic
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC
University of California, Irvine
Merck Sharp & Dohme LLC
AstraZeneca
Verastem, Inc.
National Institutes of Health Clinical Center (CC)
Exelixis
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Shanghai Henlius Biotech
Pfizer
Dana-Farber Cancer Institute
Jazz Pharmaceuticals
AstraZeneca
Seagen Inc.
Tizona Therapeutics, Inc
Essen Biotech
Genentech, Inc.
Alnylam Pharmaceuticals
Amsterdam UMC, location VUmc
Amgen
IDEAYA Biosciences
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
RemeGen Co., Ltd.
Eli Lilly and Company
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Linnaeus Therapeutics, Inc.
Sairopa B.V.
VM Oncology, LLC
Peking Union Medical College Hospital
Curacell Holding AB
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins